ERBB2 and non-small cell lung carcinoma: Given all these encouraging results, a phase III study evaluating pyrotinib versus docetaxel as second-line therapy in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation (PYRAMID-1/ NCT04447118) is now recruiting patients.